Attached files
file | filename |
---|---|
EXCEL - IDEA: XBRL DOCUMENT - Arbutus Biopharma Corp | Financial_Report.xls |
10-Q - FORM 10-Q - Arbutus Biopharma Corp | f10q_081314.htm |
EX-31.1 - EXHIBIT 31.1 - Arbutus Biopharma Corp | exh_311.htm |
EX-31.2 - EXHIBIT 31.2 - Arbutus Biopharma Corp | exh_312.htm |
EX-32.1 - EXHIBIT 32.1 - Arbutus Biopharma Corp | exh_321.htm |
EX-32.2 - EXHIBIT 32.2 - Arbutus Biopharma Corp | exh_322.htm |
EX-10.2 - EXHIBIT 10.2 - Arbutus Biopharma Corp | exh_102.htm |
Exhibit 10.1
Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.
AMENDMENT NO. 1 to PROTIVA AGRICULTURAL DEVELOPMENT COMPANY INC. OPTION AGREEMENT
THIS AMENDMENT NO. 1 to PROTIVA AGRICULTURAL DEVELOPMENT
COMPANY INC. OPTION AGREEMENT ("Amendment No. l") effective as of the last date of signature hereto ("Effective Date"), is by and among Monsanto Canada, Inc., a Canadian corporation ("Monsanto Canada"), Tekmira Pharmaceuticals Corporation, a British Columbia corporation ("Tekmira"), Protiva Biotherapeutics Inc., a British Columbia corporation ("Protiva"), and Protiva Agricultural Development Company Inc., a British Columbia corporation (the "Company").
WHEREAS, Monsanto Canada, Tekmira, Protiva, and Company (collectively the "Parties") are parties to an option agreement effective January 12, 2014 (the "Agreement"); and
WHEREAS, Parties desire to amend Exhibit B-5(i), OPTION SET-UP COMPLETION CRITERIA;
NOW, THEREFORE, in consideration of the above, the Parties hereby agree to amend the Agreement as follows:
1.
|
Exhibit B-5(i), OPTION SET-UP COMPLETION CRITERIA in the Agreement shall be replaced in its entirety by the amended and restated OPTION SET-UP COMPLETION CRITERIA attached hereto and incorporated herein by reference.
|
Upon execution, this Amendment No. 1 shall be made a part of the Agreement. Except as provided herein, all other terms and conditions of the Agreement shall remain in full force and effect.
1
IN WITNESS WHEREOF, the parties hereto have executed or caused this Amendment No. 1to be executed by their respective officers or other representatives duly authorized.
PROTIVA BIOTHERAPEUTICS INC.
|
PROTIVA AGRICULTURAL DEVELOPMENT COMPANY, INC.
|
|||
By: |
/s/ Bruce Cousins
|
By: |
/s/ Bruce Cousins
|
|
Name: |
Bruce Cousins
|
Name: |
Bruce Cousins
|
|
Title: |
Executive Vice President & CFO
|
Title: |
Executive
|
|
Address: | June 26, 2014 | Address: |
June 26, 2014
|
|
TEKMIRA PHARMACEUTICALS CORPORATION
|
MONSANTO CANADA, INC.
|
|||
By: |
/s/ Bruce Cousins
|
By: |
/s/ Robert M. McCarroll
|
|
Name: |
Bruce Cousins
|
Name: |
Robert M.McCarroll, Ph. D.
|
|
Title: |
Executive Vice President & CFO
|
Title: |
Authorized Signatory
|
|
Address: |
June 26, 2014
|
Address: |
June 26, 2014
|
|
2
EXHIBIT B-5(i)
OPTION SET-UP COMPLETION CRITERIA
[***]
3